Physician profile
John M Bundy
NPI 1821027210
$10,224.03
in general payments reported to CMS, 2019-2025
44 companies · $945 in 2025
The $945 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,867 · 2020: $961 · 2021: $2,285 · 2022: $1,672 · 2023: $1,356 · 2024: $1,138 · 2025: $945.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,439.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,439.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,218.98 | 2019-2025 | |
| Lilly USA, LLC | $1,163.80 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $950.28 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $934.35 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $774.87 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Glaxosmithkline, LLC. | $713.37 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astellas Pharma US INC | $705.36 | 2019-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $581.33 | 2020-2025 | Ubrelvy, Vraylar |
| Amarin Pharma, INC. | $467.27 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $310.59 | 2019-2023 | Trintellix |
| Amgen INC. | $308.20 | 2019-2021 | |
| Abbott Laboratories | $235.95 | 2021-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $218.18 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $196.59 | 2021-2023 | |
| Dexcom, INC. | $186.22 | 2021-2025 | Dexcom G6 Transmitter |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Bundy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.